Infection and Drug Resistance · 2018 · 33 citations · 30 references
Public HealthInfectious DiseasesDiagnostic MicrobiologyMolecular DiagnosticsTuberculosis ControlInfectious Disease Molecular TestingMycobacterial DiagnosticsPulmonary TuberculosisTuberculosis DiagnosisTuberculosis Diagnostic TestingTuberculosis EpidemiologyDrug Resistance TestingDrug Susceptibility AssaysMolecular Detection AssaysMolecular Drug Susceptibility TestingPhenotypic Drug Susceptibility TestingRifampicin Resistance TestingTuberculosis Drug ResistanceTuberculosis Molecular Testing
Background: The incidence of tuberculosis (TB), especially multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), continues to increase alarmingly worldwide. Molecular line probe assays (LPAs) are endorsed by the World Health Organization for the fast detection of MDR-TB and XDR-TB. The aim of this study was to evaluate the performance of LPAs in China. Methods: We analyzed MDR-TB and XDR-TB in 96 isolates from Beijing by using culture-based drug susceptibility testing (DST) and LPAs to compare the detection rate of the two methods. Results: Compared to phenotypic DST, the GenoType ® MTBDR plus and MTBDR sl , respectively, showed a sensitivity of 98.7% and a specificity of 88.9% for detection of rifampicin resistance, 82.1% and 94.4% for isoniazid, 89.7% and 94.4% for levofloxacin, 60.0% and 98.7% for amikacin/capreomycin, and 57.5% and 98.2% for ethambutol. The sensitivity and specificity of LPAs, respectively, were 80.8% and 100% for MDR-TB and 50.0% and 97.6% for XDR-TB. Mutations in codon S531L of the rpoB gene and S315T1 of the KatG gene were dominated in MDR-TB strains. The most frequently observed mutations were in codon A90V of the gyrA gene, A1401G of the rrs gene, and M306V of the embB gene, according to the MTBDR sl results. Conclusion: Our study showed that, in combination with phenotypic DST, application of the LPAs might be an efficient and reliable supplementary DST assay for rapid susceptibility screening of MDR-TB and XDR-TB. Using LPAs in countries with high MDR/XDR burden allows for appropriate and timely treatment, which will reduce transmission rates and morbidity, and improve treatment outcomes in patients. Keywords: Mycobacterium tuberculosis , MDR-TB, XDR-TB, line probe assay, phenotypic drug susceptibility testing
30
National Survey of Drug-Resistant Tuberculosis in China
Yanlin Zhao, Shaofa Xu, Lixia Wang et al. · New England Journal of Medicine · 2012 · 645 citations · Full text
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.
G Canetti, S. Froman, J. Grosset et al. · PubMed · 1963 · 538 citations
Veterinary Medicine, Infectious Diseases, Antimicrobial Resistance +15
Doris Hillemann, Sabine Rüsch–Gerdes, Elvira Richter · Journal of Clinical Microbiology · 2007 · 346 citations · Full text